arrow
G

Gianmario Candore

Bayer AG
H指数:13
被引数:1,196

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update

WHO-ISoP 药物警戒课程:2026 年更新

2026-09-200
OAAI
Recommendations to Enable Broader Use of Real-World Evidence to Inform Decision-Making Throughout Pharmacovigilance Signal Management

关于利用真实世界证据支持药物警戒信号管理全过程中决策制定的建议

2025-10-010
OAAI
FRAME: Framework for Real-World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making

框架:用于减轻疗效/效果证据不确定性的真实世界证据评估框架——对监管和卫生技术评估决策制定的评估

2025-06-100
OAAI
Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance
2025-04-010
OAAI
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
2024-05-0735
OAAI
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
2024-05-0772
OAAI
Good Signal Detection Practices: Evidence from IMI PROTECT
2016-03-07114
OAAI